Ann: Immuron CEO to present at Emerging Growth Conference, page-6

I think we have a manager who is good at the commercial side and running a trial program.

ETEC results in August will be crucial for product
validation and so will the armed forces phase4 trial with results due first half( realistically) 2025. So company changing events coming up.

C-diff moving forward is good but commercial return is too far away to factor.

So next year they are talking about starting a C-diff phase2 and a Travelan phase3? Steven used the word “probably” for the phase3 Travelan trial
and earlier in the presentation he said “ planning to” . There’s a little bit of confusion in messaging there.

What about ETEC? If results are good do they plan on moving that into phase3?

With a steep incline on sales growth, 70% gross margins and solid trial activity moving forward it’s hard not to see us as cheap atm.

Worth a punt at current lvl’s, imo.